Myriad Genetics 2025 Q3 Earnings Net Loss Widens by 24% Despite Revenue Beat

Myriad Genetics (MYGN) reported mixed third-quarter 2025 results, with revenue exceeding expectations while losses deepened. The company reiterated full-year guidance despite a 3.6% year-over-year revenue decline and a 24% wider net loss. Strategic initiatives and operational improvements were highlighted, but profitability challenges persist.

Revenue

Hereditary Cancer led the revenue streams, , , respectively. . , .

Earnings/Net Income

, . The EPS decline reflects ongoing operational pressures and strategic investments.

Post-Earnings Price Action Review

Following the earnings release, . The mixed performance underscores investor uncertainty about the company’s ability to balance growth initiatives with profitability.

CEO Commentary

, President and CEO, emphasized disciplined execution and progress in key areas. “Our focus on the cancer care continuum and strategic partnerships, like the SOPHiA Genetics collaboration, positions us for long-term growth,” he stated. .

Guidance

. , aiming to grow revenue faster than operating expenses.

Additional News

1. Strategic Collaboration: Myriad announced a partnership with SOPHiA Genetics to develop a global liquid biopsy companion diagnostic test, enhancing its precision medicine offerings.

2. C-Level Leadership: Ben Wheeler, a 14-year company veteran, assumed the role of CFO, emphasizing financial discipline and strategic capital deployment.

3. Product Launches: The company expanded its Foresight Carrier Screen Universal Plus Panel with two new genes, targeting growth in prenatal testing.